{"product_id":"infectious-diseases-in-vitro-diagnostics-market-by-product-instruments-reagents-software-technology-immunochemistry-microbiology-molecular-diagnostics-indication-end-user-global-forecast-2023-2030","title":"Infectious Diseases In-Vitro Diagnostics Market by Product (Instruments, Reagents, Software), Technology (Immunochemistry, Microbiology, Molecular Diagnostics), Indication, End-user - Global Forecast 2023-2030","description":"\u003cp\u003eInfectious Diseases In-Vitro Diagnostics Market by Product (Instruments, Reagents, Software), Technology (Immunochemistry, Microbiology, Molecular Diagnostics), Indication, End-user - Global Forecast 2023-2030\u003cbr\u003e\nThe Infectious Diseases In-Vitro Diagnostics Market is projected to reach USD 79.95 billion by 2030 from USD 45.85 billion in 2022, at a CAGR of 7.19% during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation \u0026amp; Coverage:\u003c\/p\u003e\n\n\u003cp\u003eThis research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Infectious Diseases In-Vitro Diagnostics Market.Based on Product, market is studied across Instruments, Reagents, and Software. The Reagents commanded largest market share of 58.89% in 2022, followed by Instruments.Based on Technology, market is studied across Immunochemistry, Microbiology, and Molecular Diagnostics. The Molecular Diagnostics commanded largest market share of 52.27% in 2022, followed by Microbiology.Based on Indication, market is studied across Candidiasis, Chlamydia, Clostridium difficile, CRE, Gastroenteritis, Gonorrhea, Hepatitis, HIV, HPV, MRSA, Respiratory Virus, Streptococcus, TB and Drug-resistant TB, and VRE. The Hepatitis commanded largest market share of 9.39% in 2022, followed by TB and Drug-resistant TB.Based on End-user, market is studied across Central Laboratories, Point of Care, and Rapid Test Kit. The Central Laboratories commanded largest market share of 42.54% in 2022, followed by Point of Care.Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East \u0026amp; Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East \u0026amp; Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East \u0026amp; Africa commanded largest market share of 36.96% in 2022, followed by Asia-Pacific.Market Statistics:\u003c\/p\u003e\n\n\u003cp\u003eThe report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.\u003c\/p\u003e\n\n\u003cp\u003eFPNV Positioning Matrix:\u003c\/p\u003e\n\n\u003cp\u003eThe FPNV Positioning Matrix is an indispensable tool for assessing the Infectious Diseases In-Vitro Diagnostics Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.\u003c\/p\u003e\n\n\u003cp\u003eMarket Share Analysis:\u003c\/p\u003e\n\n\u003cp\u003eThe Market Share Analysis offers invaluable insights into the vendor landscape Infectious Diseases In-Vitro Diagnostics Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.\u003c\/p\u003e\n\n\u003cp\u003eKey Company Profiles:\u003c\/p\u003e\n\n\u003cp\u003eThe report delves into recent significant developments in the Infectious Diseases In-Vitro Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMérieux SA, Danaher Corporation, DiaSorin S.p.A, Epitope Diagnostics, Inc., F. Hoffmann La-Roche Ltd., Genspeed Biotech GmbH, Grifols, S.A., Hologic, Inc., Illumina, Inc., InBios International, Inc., Koninklijke Philips N.V., Laboratory Corporation Of America Holdings, Merck KGaA, Meril Life Sciences Pvt. Ltd., OraSure Technologies, Inc., PerkinElmer, Inc., Qiagen N.V., Quest Diagnostics, Quidel Corporation, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., Trinity Biotech PLC, Uniogen Oy, and Vela Diagnostics.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers valuable insights on the following aspects:Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.Competitive Assessment \u0026amp; Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.Product Development \u0026amp; Innovation: Intelligent insights on future technologies, R\u0026amp;D activities, and breakthrough product developments.The report addresses key questions such as:What is the market size and forecast for the Infectious Diseases In-Vitro Diagnostics Market?Which products, segments, applications, and areas hold the highest investment potential in the Infectious Diseases In-Vitro Diagnostics Market?What is the competitive strategic window for identifying opportunities in the Infectious Diseases In-Vitro Diagnostics Market?What are the latest technology trends and regulatory frameworks in the Infectious Diseases In-Vitro Diagnostics Market?What is the market share of the leading vendors in the Infectious Diseases In-Vitro Diagnostics Market?Which modes and strategic moves are suitable for entering the Infectious Diseases In-Vitro Diagnostics Market?\u003c\/p\u003e\n\n\u003cp\u003eNote: PDF \u0026amp; Excel + Online Access - 1 Year\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"October, 2023 \/ 185 Pages \/ MCW16238074","offer_id":47652830937394,"sku":null,"price":5939.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/infectious-diseases-in-vitro-diagnostics-market-by-product-instruments-reagents-software-technology-immunochemistry-microbiology-molecular-diagnostics-indication-end-user-global-forecast-2023-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}